Physician profile
John E Nix
NPI 1972598837
$4,535.56
in general payments reported to CMS, 2019-2025
33 companies · $778 in 2025
The $778 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $479 · 2021: $848 · 2022: $570 · 2023: $797 · 2024: $486 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042 · Debt Forgiveness: $18.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,041.85 |
| Debt Forgiveness | $18.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,080.71 | 2021-2025 | |
| Novo Nordisk INC | $444.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $408.29 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $323.20 | 2019-2023 | Repatha, Otezla |
| Pfizer INC. | $249.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $240.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $162.86 | 2020-2024 | Mounjaro, Trulicity, Zepbound |
| Sanofi-Aventis U.S. LLC | $162.75 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $149.23 | 2019-2025 | Gardasil 9, Capvaxive, Steglujan |
| Genentech USA, INC. | $136.49 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $131.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $124.83 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $99.77 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $99.19 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.33 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $79.77 | 2020-2021 | |
| Allergan, INC. | $67.38 | 2019-2020 | |
| Exact Sciences Corporation | $59.78 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.12 | 2020-2024 | Jardiance, Synjardy |
| Kowa Pharmaceuticals America, INC. | $46.02 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $42.47 | 2023-2024 | Rexulti |
| Corcept Therapeutics | $40.77 | 2025 | Korlym |
| Astellas Pharma US INC | $31.77 | 2019-2023 | Veozah |
| Inspire Medical Systems, INC. | $28.76 | 2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.91 | 2019 | |
| Globus Medical, INC. | $26.10 | 2025 | Senza |
| Almatica Pharma LLC | $25.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.46 | 2021 | |
| Baxter Healthcare | $18.80 | 2024 | |
| Dexcom, INC. | $18.65 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $14.82 | 2023 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $13.30 | 2023 | Camzyos |
| Esperion Therapeutics, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.